Cisplatin is an effective chemotherapeutic agent whose clinical use is limited by dose-dependent off-target toxicities, particularly hepatic and cardiac injury. The present study investigated the protective efficacy of rutin-mediated selenium nanoparticles (RUT-SeNPs) against cisplatin-induced hepato-cardiotoxicity in rats and compared their effects against those of free rutin and sodium selenite. RUT-SeNPs were characterized using dynamic light scattering, zeta potential analysis, transmission electron microscopy, X-ray diffraction, and UV–visible spectroscopy. Thirty-five male rats were randomly assigned to five groups: control (CON), cisplatin (CIS), CIS + Rutin, CIS + selenium, and CIS + RUT-SeNPs. Cisplatin administration caused marked hepatic and cardiac injury, as evidenced by altered liver-function indices, elevated cardiac injury biomarkers, oxidative stress, inflammatory activation, endoplasmic reticulum stress, and apoptosis. These effects were associated with increased lipid peroxidation, depletion of endogenous antioxidants, KEAP1 upregulation, Nrf2 suppression, activation of the TLR4/MAPK/NF-κB inflammatory axis, elevated TNF-α, IL-6, and COX-2 levels, and increased mRNA expression of the ER stress-related genes PERK, ATF4, ATF6, and CHOP. Cisplatin also promoted mitochondrial apoptosis, as indicated by increased Bax expression and cytochrome c release together with reduced Bcl-2 levels. Although rutin and sodium selenite partially mitigated these alterations, RUT-SeNPs produced the most pronounced protective effects by restoring redox homeostasis, suppressing inflammatory signaling, reducing the elevated expression of ER stress-related genes, and limiting mitochondrial apoptotic activation. These molecular improvements were accompanied by substantial preservation of the hepatic and cardiac histoarchitecture. Collectively, these results indicate that RUT-SeNPs may represent a promising nanoformulation for reducing cisplatin-induced hepato-cardiac toxicity through coordinated modulation of oxidative stress, inflammation, endoplasmic reticulum stress, and apoptosis.
N. Mahran, Khaled M. Alam-ElDein, Mohamed A. Ali et al.· International Journal of Mol...· 0 citations
Background Miconazole (MN) is widely used to treat superficial fungal infections; however, limited skin penetration and short residence time restrict its therapeutic efficacy. This study aimed to develop and statistically optimize MN-loaded sterosomes (STEs) to enhance topical antifungal activity. Methods A central composite rotatable design (CCRD) was applied using Design-Expert® software to study the effects of cholesterol amount (mg) and sonication time (min) on vesicle size (VS), zeta potential (ZP), and entrapment efficiency (EE%). Vesicle morphology was characterized by transmission electron microscopy (TEM), and drug entrapment was confirmed using X-ray diffraction (XRD). The optimized formulation was incorporated into a hydroxypropyl methylcellulose (HPMC) gel and evaluated for in vitro release and in-vivo antifungal efficacy in a Wistar albino rats cutaneous candidiasis model (n = 6) following topical administration of optimized MN-loaded sterosome gel 1% w/w for ten days. Results The optimized formulation showed a desirability of 0.63 and consisted of 140.86 mg cholesterol and 8.99 min sonication time. It demonstrated vesicle size: 498.54 ± 6.12 nm, zeta potential: 40.82 ± 1.24 mV, entrapment efficiency: 77.41 ± 1.43%. MN release from STEs was significantly higher than the drug suspension. TEM images showed spherical non-aggregated vesicles. XRD patterns indicated successful MN entrapment. In-vivo, MN-STE gel produced significantly greater antifungal activity than commercial Daktarin® cream at a lower dose, which was consistent with histopathological improvement. Conclusion MN-loaded sterosomes enhanced drug entrapment, release, and antifungal efficacy while enabling dose reduction, representing a promising carrier for topical miconazole delivery.
Maha Alsunbul, R. Zaki, Ghaida N. Alnuwaybit et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.